Open AccessLncRNA HLA Complex Group 11 Knockdown Alleviates Cisplatin Resistance in Gastric Cancer by Targeting the miR-144-3p/UBE2D1 Axis
Author(s) -
Yu Liu,
Liqin Wang,
Xin Xu,
Heng Sun,
Leilei Wu
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s329846
Subject(s) - gene knockdown , cisplatin , mtt assay , viability assay , microrna , chemistry , cancer research , cancer , microbiology and biotechnology , competing endogenous rna , long non coding rna , biology , downregulation and upregulation , in vitro , apoptosis , gene , biochemistry , chemotherapy , genetics
Cisplatin (DDP) treatment is one of the most predominant chemotherapeutic strategies for patients with gastric cancer (GC). LncRNA noncoding RNA HLA complex group 11 (lncRNA HCG11) has been confirmed to promote GC progression. This study attempted to investigate the underlying molecular mechanism of HCG11 in DDP resistance of GC.